He has published several articles in leading professional journals, including the Journal of Genes and Immunology, the Journal of Biological Chemistry and the Blood Journal.
DENVER, CO, September 30, 2024 /24-7PressRelease/ -- Mark Brunvand, MD, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Brunvand is a recognized medical professional with over 40 years of experience as an oncologist specializing in cellular immunotherapy, blood cancer care and stem cell transplantation. Since 2022, he has also been the managing medical consulting partner at MWB Consulting LLC in Denver, involved in the clinical development for cellular immune therapy of high-risk, relapsed, refractory malignancies, clinical trial design, implementation and management, and more.
A career marked by significant contributions to immunotherapy and transplantation for hematological malignancies, Dr. Brunvand's expertise is built on a foundation of ethical, data-driven solutions and a commitment to patient engagement and education. From 2020 to 2023, he was the field medical director for CAR T-cell therapy at Bristol Myers Squibb. Dr. Brunvand also served as the transplant medical director at Cigna between 2017 and 2020. His tenure at the Colorado Blood Cancer Institute from 2010 to 2016 saw him directing the unrelated donor transplantation program, a role he previously held at the Rocky Mountain Cancer Center between 1997 and 2010.
In addition to his clinical expertise, Dr. Brunvand was a faculty member at Oregon Health and Science University, where he served as an assistant professor of medicine and the director of the unrelated donor program from 1995 to 1997. Earlier in his career, he was an associate in clinical research at Fred Hutchinson Cancer Research Center between 1991 and 1995.
As a seasoned researcher, Dr. Brunvand's contributions are notable, resulting in several articles in leading professional journals, including the Journal of Genes and Immunology, the Journal of Biological Chemistry and the Blood Journal.
Possessing a rich educational background, Dr. Brunvand received a bachelor's degree in chemistry from Colorado State University in 1978 and a Doctor of Medicine with honors from the University of Colorado School of Medicine in 1982. He also completed a residency in internal medicine at the University of Colorado from 1982 to 1985, followed by fellowships Immunology with lab work on T-cell gene regulation in the Laboratory of Immunoregulation at National Institute of Allergy and Infectious Diseases from 1985 to 1988. He completed an oncology fellowship at the University of Washington and Fred Hutchinson Cancer Research Center from 1988 through 1991. Dr. Brunvand is board-certified by the American Board of Medical Examiners, the American Board of Internal Medicine and the American Board of Medical Oncology.
Dr. Brunvand is actively involved in several professional organizations, including the American Association for the Advancement of Science, the American Society of Clinical Oncology, the American Society of Hematology and the American Society of Transplantation and Cellular Therapy. He is also a fellow of the American College of Internal Medicine.
Throughout his career, Dr. Brunvand has been recognized with numerous awards, including an American Society of Clinical Oncology Young Investigator in 1990, the Marion L. Krippaehne Humanism Award from Oregon Health and Science University in 1996, and the University of Colorado Housestaff Outstanding Teaching Award in 2006.
In addition to his professional achievements, Dr. Brunvand is dedicated to civic engagement. He has been an inspector for and on multiple committees at the Foundation for Accreditation of Cellular Therapy since 2002. Dr. Brunvand is also a founding board member of the Radiation Injury Treatment Network at the National Marrow Donor Program and is on the scientific advisory board member for the Gates Institute for Regenerative Medicine at the University of Colorado.
Looking ahead, Dr. Brunvand gain approval for next-generation cellular therapies through his consulting work, significantly improving treatment outcomes for patients with relapsed and refractory cancer while reducing side effects. His dedication to advancing medical science continues to make a meaningful difference in patients' lives.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
# # #